Novartis CTBM100C2401E1
Back to Studies Overview
[1]
The ECFS-CTN cannot guarantee that the information provided here is comprehensive. Please go to the ClinicalTrials.gov link for detailed and up-to-date information on study background, eligibility criteria, study design, outcome measures, study status, participating sites, sponsor contact information and timelines.
You can also contact the CTN coordinating centre for additional information: ECFS-CTN@uzleuven.be [2]
| Study Name on ClinicalTrials.gov [3] |
Extension. Long-term Safety Study in CF Patients: Single Arm TIP |
| Study Drug | Tobramycin inhalation powder |
| T | Anti-infective |
| Study Title | A 48 Week Extension to CTBM100C2401, a Single Arm, Open-label, Multicenter, Phase IV Extension Trial to Assess Long Term Safety of Tobramycin Inhalation Powder (TIP) in Patients With Cystic Fibrosis Who Completed Participation in CTBM100C2401 |
| Study Phase | 4 |
| Study Sponsor | Novartis |
| Link on clincaltrials.gov [3] | |
| Participating ECFS-CTN sites | Italy: Firenze, Rome, Verona Spain: Barcelona |
| Age | 6 Years and older |
